AstraZeneca reports Phase III survival benefit for Tagrisso–Orpathys lung cancer combination
Astra Zeneca logo on building ©Adobe Stock Images AstraZeneca (LSE:AZN) has reported positive results from the global Phase…
AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
Investing.com – AstraZeneca shares surged approximately 6% on Wednesday after a senior source told Reuters there are “no…
EU Clears AZN’s Etcamah Combo for First-Line ER-Positive Breast Cancer
AstraZeneca AZN announced that the European Commission (EC) has approved Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for…
AstraZeneca and Abbisko collaborate on NSCLC combination therapy trial
AstraZeneca has signed a strategic collaboration agreement with Abbisko Therapeutics to study the combined use of Tagrisso (osimertinib)…
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint OCALA, Fla.,…
FDA Extends Review Time for AZN’s Camizestrant Combo in Breast Cancer
AstraZeneca AZN announced that the FDA will extend the Prescription Drug User Fee Act (PDUFA) date for reviewing the…
Rio Tinto and Glencore release statements regarding possible merger
Save to read list
…